AIM News & Events

AIM ImmunoTech announced the preliminary results of its previously announced rights offering which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8M. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer Solutions. Each right entitled the holder to purchase one unit, at a subscription price of $1,000 per Unit, consisting of one share of the Company's Series G Convertible Preferred Stock, and 2,000 Class G Common Stock Purchase Warrants to purchase the Company's Common Stock. The Company anticipates the closing of the Rights Offering will occur on or about March 6, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of DTC, as applicable, shares of the Preferred Stock and Warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders.

AIM ImmunoTech (AIM) announced an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design AIM's anticipated Phase 3 clinical trial in the use of the Company's drug Ampligen in the treatment of late-stage pancreatic cancer. AIM CEO Thomas Equels states: "The ongoing Phase 2 DURIPANC clinical trial of Ampligen and AstraZeneca's durvalumab in the treatment of late-stage pancreatic cancer is producing promising results. Based on the success so far, as well as anticipated final patient enrollment later this year, we believe it is now time to start mapping out the next steps for AIM's development of Ampligen as a therapy for pancreatic cancer. AIM's scientific team will work closely with Thermo Fisher's experts in the design of a Phase 3 study and we look forward to their expertise and guidance in this critical endeavor. Pancreatic cancer is a deadly unmet medical need - and AIM believes that Ampligen could be a gamechanger in the treatment of pancreatic cancer."

AIM ImmunoTech announced updated terms for its previously announced rights offering. Each subscription right now entitles holders to purchase one unit, each Unit consisting of one share of the Company's Series G Convertible Preferred Stock, and 2,000 Class G Common Stock Purchase Warrants to purchase the Company's Common Stock at a subscription price of $1,000 per Unit. Each share of Preferred Stock will be convertible, at the option of the holder at any time, into 1,000 shares of Common Stock, which is equal to the quotient of the stated value of the Preferred Stock divided by the conversion price. Each Warrant will be exercisable for one share of Common Stock at an exercise price of $1.00 per share from the date of issuance through its expiration five years from the date of issuance. All record holders of rights certificates that wish to participate in the rights offering must deliver a properly completed and signed rights certificate, together with payment of the subscription price for both basic subscription rights and any over-subscription privilege election, to the Subscription Agent, to be received before 5:00 p.m. Eastern Time on March 3, 2026.